Peter Rahmer Net Worth

The estimated Net Worth of Peter Rahmer is at least $4.03 Миллион dollars as of 29 July 2024. Mr Rahmer owns over 42,359 units of Relay Therapeutics stock worth over $3,041,369 and over the last 2 years he sold RLAY stock worth over $984,382.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Rahmer RLAY stock SEC Form 4 insiders trading

Mr has made over 14 trades of the Relay Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 42,359 units of RLAY stock worth $353,274 on 29 July 2024.

The largest trade he's ever made was selling 80,909 units of Relay Therapeutics stock on 3 June 2024 worth over $542,090. On average, Mr trades about 7,766 units every 32 days since 2023. As of 29 July 2024 he still owns at least 391,929 units of Relay Therapeutics stock.

You can see the complete history of Mr Rahmer stock trades at the bottom of the page.

Mr. Peter Rahmer biography

Peter Rahmer is the Sr. VP of Corp. Affairs & Investor Relations at Relay Therapeutics.

What's Mr Rahmer's mailing address?

Peter's mailing address filed with the SEC is 339, Binney Street, East Cambridge, Cambridge, Middlesex County, Massachusetts, 02142, United States.

Insiders trading at Relay Therapeutics

Over the last 4 years, insiders at Relay Therapeutics have traded over $234,228,237 worth of Relay Therapeutics stock and bought 110,000 units worth $2,200,000 . The most active insiders traders include Rock Ventures Iii, L.P.Thir..., Sanjiv Patel и Donald A Bergstrom. On average, Relay Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $406,570. The most recent stock trade was executed by Thomas Catinazzo on 29 July 2024, trading 10,780 units of RLAY stock currently worth $92,277.

What does Relay Therapeutics do?

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Mr Rahmer stock trades at Relay Therapeutics

Relay Therapeutics executives and stock owners

Relay Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS,
  CEO, Pres & Director
• Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A.,
  CEO, Pres & Director
• Dr. Donald A. Bergstrom M.D., Ph.D.,
  Exec. VP and Head of R&D
• Brian R. Adams J.D.,
  Gen. Counsel & Sec.
• Dr. Mark Murcko Ph.D.,
  Co-Founder & Director
• Alexis A. Borisy A.M.,
  Co-Founder & Independent Chairman
• Jim Watters Ph.D.,
  Sr. VP & Head of Late Research
• Andy Porter,
  Exec. VP & Chief People Officer
• Dr. Deborah Palestrant Ph.D.,
  VP of Corp. Devel. & Strategy
• Peter Rahmer,
  Sr. VP of Corp. Affairs & Investor Relations
• Thomas Catinazzo,
  Sr. VP of Fin.
• Mark Murcko,
  
• Alexis Borisy,
  
• Sekar Kathiresan,
  
• Linda A Hill,
  
• Douglas S Ingram,
  
• Brian Adams,
  Chief Legal Officer
• Donald A Bergstrom,
  President, R&D
• Llcshaw David E Picularium,,
  
• Jami Rubin,
  
• Sanjiv Patel,
  President and CEO
• Pauling (Cayman) Ltd Softba...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Andy Porter,
  Chief Administrative Officer
• Thomas Catinazzo,
  Chief Financial Officer
• Peter Rahmer,
  See remarks
• Laura Shawver,